Skip to main content
Top
Published in: Thrombosis Journal 1/2023

Open Access 01-12-2023 | Anticoagulant | Review

Current and future strategies to monitor and manage coagulation in ECMO patients

Authors: Saeedreza Zeibi Shirejini, Josie Carberry, Zoe K. McQuilten, Aidan J. C. Burrell, Shaun D. Gregory, Christoph E. Hagemeyer

Published in: Thrombosis Journal | Issue 1/2023

Login to get access

Abstract

Extracorporeal membrane oxygenation (ECMO) can provide life-saving support for critically ill patients suffering severe respiratory and/or cardiac failure. However, thrombosis and bleeding remain common and complex problems to manage. Key causes of thrombosis in ECMO patients include blood contact to pro-thrombotic and non-physiological surfaces, as well as high shearing forces in the pump and membrane oxygenator. On the other hand, adverse effects of anticoagulant, thrombocytopenia, platelet dysfunction, acquired von Willebrand syndrome, and hyperfibrinolysis are all established as causes of bleeding. Finding safe and effective anticoagulants that balance thrombosis and bleeding risk remains challenging. This review highlights commonly used anticoagulants in ECMO, including their mechanism of action, monitoring methods, strengths and limitations. It further elaborates on existing anticoagulant monitoring strategies, indicating their target range, benefits and drawbacks. Finally, it introduces several highly novel approaches to real-time anticoagulation monitoring methods including sound, optical, fluorescent, and electrical measurement as well as their working principles and future directions for research.
Literature
1.
go back to reference Combes A, Price S, Slutsky AS, Brodie D. Temporary circulatory support for cardiogenic shock. The Lancet. 2020;396(10245):199–212.CrossRef Combes A, Price S, Slutsky AS, Brodie D. Temporary circulatory support for cardiogenic shock. The Lancet. 2020;396(10245):199–212.CrossRef
2.
go back to reference Fanelli V, Giani M, Grasselli G, Mojoli F, Martucci G, Grazioli L, et al. Extracorporeal membrane oxygenation for COVID-19 and influenza H1N1 associated acute respiratory distress syndrome: a multicenter retrospective cohort study. Crit Care. 2022;26(1):34.CrossRef Fanelli V, Giani M, Grasselli G, Mojoli F, Martucci G, Grazioli L, et al. Extracorporeal membrane oxygenation for COVID-19 and influenza H1N1 associated acute respiratory distress syndrome: a multicenter retrospective cohort study. Crit Care. 2022;26(1):34.CrossRef
3.
go back to reference Frerou A, Lesouhaitier M, Gregoire M, Uhel F, Gacouin A, Reizine F, et al. Venoarterial extracorporeal membrane oxygenation induces early immune alterations. Crit Care. 2021;25(1):9.CrossRef Frerou A, Lesouhaitier M, Gregoire M, Uhel F, Gacouin A, Reizine F, et al. Venoarterial extracorporeal membrane oxygenation induces early immune alterations. Crit Care. 2021;25(1):9.CrossRef
4.
go back to reference Chan CHH, Ki KK, Zhang M, Asnicar C, Cho HJ, Ainola C, et al. Extracorporeal membrane oxygenation-induced hemolysis: An in vitro study to appraise causative factors. Membranes. 2021;11(5):313. Chan CHH, Ki KK, Zhang M, Asnicar C, Cho HJ, Ainola C, et al. Extracorporeal membrane oxygenation-induced hemolysis: An in vitro study to appraise causative factors. Membranes. 2021;11(5):313.
5.
go back to reference Heuts S, Makhoul M, Mansouri AN, Taccone FS, Obeid A, Belliato M, et al. Defining and understanding the “extra-corporeal membrane oxygenation gap” in the veno-venous configuration: timing and causes of death. Artif Organs. 2022;46(3):349–61.CrossRef Heuts S, Makhoul M, Mansouri AN, Taccone FS, Obeid A, Belliato M, et al. Defining and understanding the “extra-corporeal membrane oxygenation gap” in the veno-venous configuration: timing and causes of death. Artif Organs. 2022;46(3):349–61.CrossRef
6.
go back to reference Vaquer S, de Haro C, Peruga P, Oliva JC, Artigas A. Systematic review and meta-analysis of complications and mortality of veno-venous extracorporeal membrane oxygenation for refractory acute respiratory distress syndrome. Ann Intensive Care. 2017;7(1):1–13. Vaquer S, de Haro C, Peruga P, Oliva JC, Artigas A. Systematic review and meta-analysis of complications and mortality of veno-venous extracorporeal membrane oxygenation for refractory acute respiratory distress syndrome. Ann Intensive Care. 2017;7(1):1–13.
7.
go back to reference Bembea MM, Annich G, Rycus P, Oldenburg G, Berkowitz I, Pronovost P. Variability in anticoagulation management of patients on extracorporeal membrane oxygenation: an international survey. Pediatr Crit Care Med. 2013;14(2): e77.CrossRef Bembea MM, Annich G, Rycus P, Oldenburg G, Berkowitz I, Pronovost P. Variability in anticoagulation management of patients on extracorporeal membrane oxygenation: an international survey. Pediatr Crit Care Med. 2013;14(2): e77.CrossRef
8.
go back to reference Schünemann HJ, Cushman M, Burnett AE, Kahn SR, Beyer-Westendorf J, Spencer FA, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients. Blood Adv. 2018;2(22):3198–225.CrossRef Schünemann HJ, Cushman M, Burnett AE, Kahn SR, Beyer-Westendorf J, Spencer FA, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients. Blood Adv. 2018;2(22):3198–225.CrossRef
9.
go back to reference Zangrillo A, Landoni G, Biondi-Zoccai G, Greco M, Greco T, Frati G, et al. A meta-analysis of complications and mortality of extracorporeal membrane oxygenation. Crit Care Resusc. 2013;15(3):172–8. Zangrillo A, Landoni G, Biondi-Zoccai G, Greco M, Greco T, Frati G, et al. A meta-analysis of complications and mortality of extracorporeal membrane oxygenation. Crit Care Resusc. 2013;15(3):172–8.
10.
go back to reference Thiagarajan RR, Barbaro RP, Rycus PT, Mcmullan DM, Conrad SA, Fortenberry JD, et al. Extracorporeal life support organization registry international report 2016. ASAIO J. 2017;63(1):60–7.CrossRef Thiagarajan RR, Barbaro RP, Rycus PT, Mcmullan DM, Conrad SA, Fortenberry JD, et al. Extracorporeal life support organization registry international report 2016. ASAIO J. 2017;63(1):60–7.CrossRef
11.
go back to reference Bhat AG, Golchin A, Pasupula DK, Hernandez-Montfort JA. Right sided intracardiac thrombosis during veno-arterial extracorporeal membrane oxygenation: a case report and literature review. Case Rep Crit Care. 2019;2019:8594681. Bhat AG, Golchin A, Pasupula DK, Hernandez-Montfort JA. Right sided intracardiac thrombosis during veno-arterial extracorporeal membrane oxygenation: a case report and literature review. Case Rep Crit Care. 2019;2019:8594681.
12.
go back to reference Weber C, Deppe AC, Sabashnikov A, Slottosch I, Kuhn E, Eghbalzadeh K, et al. Left ventricular thrombus formation in patients undergoing femoral veno-arterial extracorporeal membrane oxygenation. Perfusion. 2018;33(4):283–8.CrossRef Weber C, Deppe AC, Sabashnikov A, Slottosch I, Kuhn E, Eghbalzadeh K, et al. Left ventricular thrombus formation in patients undergoing femoral veno-arterial extracorporeal membrane oxygenation. Perfusion. 2018;33(4):283–8.CrossRef
13.
go back to reference Parzy G, Daviet F, Persico N, Rambaud R, Scemama U, Adda M, et al. Prevalence and risk factors for thrombotic complications following venovenous extracorporeal membrane oxygenation: a CT scan study. Crit Care Med. 2020;48(2):192–9.CrossRef Parzy G, Daviet F, Persico N, Rambaud R, Scemama U, Adda M, et al. Prevalence and risk factors for thrombotic complications following venovenous extracorporeal membrane oxygenation: a CT scan study. Crit Care Med. 2020;48(2):192–9.CrossRef
14.
go back to reference Abruzzo A, Gorantla V, Thomas SE. Venous thromboembolic events in the setting of extracorporeal membrane oxygenation support in adults: a systematic review. Thromb Res. 2022;212:58–71.CrossRef Abruzzo A, Gorantla V, Thomas SE. Venous thromboembolic events in the setting of extracorporeal membrane oxygenation support in adults: a systematic review. Thromb Res. 2022;212:58–71.CrossRef
15.
go back to reference Levy JH, Connors JM. Heparin resistance - clinical perspectives and management strategies. N Engl J Med. 2021;385(9):826–32.CrossRef Levy JH, Connors JM. Heparin resistance - clinical perspectives and management strategies. N Engl J Med. 2021;385(9):826–32.CrossRef
16.
go back to reference Fisser C, Winkler M, Malfertheiner MV, Philipp A, Foltan M, Lunz D, et al. Argatroban versus heparin in patients without heparin-induced thrombocytopenia during venovenous extracorporeal membrane oxygenation: a propensity-score matched study. Crit Care. 2021;25(1):160.CrossRef Fisser C, Winkler M, Malfertheiner MV, Philipp A, Foltan M, Lunz D, et al. Argatroban versus heparin in patients without heparin-induced thrombocytopenia during venovenous extracorporeal membrane oxygenation: a propensity-score matched study. Crit Care. 2021;25(1):160.CrossRef
17.
go back to reference Northrop MS, Sidonio RF, Phillips SE, Smith AH, Daphne HC, Pietsch JB, et al. The use of an extracorporeal membrane oxygenation anticoagulation laboratory protocol is associated with decreased blood product use, decreased hemorrhagic complications, and increased circuit life. Pediatr Crit Care Med. 2015;16(1):66–74.CrossRef Northrop MS, Sidonio RF, Phillips SE, Smith AH, Daphne HC, Pietsch JB, et al. The use of an extracorporeal membrane oxygenation anticoagulation laboratory protocol is associated with decreased blood product use, decreased hemorrhagic complications, and increased circuit life. Pediatr Crit Care Med. 2015;16(1):66–74.CrossRef
18.
go back to reference Monagle P, Chan AKC, Goldenberg NA, Ichord RN, Journeycake JM, Nowak-Göttl U, et al. Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e737S-e801S. Monagle P, Chan AKC, Goldenberg NA, Ichord RN, Journeycake JM, Nowak-Göttl U, et al. Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e737S-e801S.
19.
go back to reference Pollak U, Yacobobich J, Tamary H, Dagan O, Manor-Shulman O. Heparin-induced thrombocytopenia and extracorporeal membrane oxygenation: a case report and review of the literature. J Extra Corpor Technol. 2011;43(1):5–12. Pollak U, Yacobobich J, Tamary H, Dagan O, Manor-Shulman O. Heparin-induced thrombocytopenia and extracorporeal membrane oxygenation: a case report and review of the literature. J Extra Corpor Technol. 2011;43(1):5–12.
20.
go back to reference Scott LK, Grier LR, Conrad SA. Heparin-induced thrombocytopenia in a pediatric patient receiving extracorporeal support and treated with argatroban. Pediatr Crit Care Med. 2006;7(3):255–7.CrossRef Scott LK, Grier LR, Conrad SA. Heparin-induced thrombocytopenia in a pediatric patient receiving extracorporeal support and treated with argatroban. Pediatr Crit Care Med. 2006;7(3):255–7.CrossRef
21.
go back to reference Glick D, Dzierba AL, Abrams D, Muir J, Eisenberger A, Diuguid D, et al. Clinically suspected heparin-induced thrombocytopenia during extracorporeal membrane oxygenation. J Crit Care. 2015;30(6):1190–4.CrossRef Glick D, Dzierba AL, Abrams D, Muir J, Eisenberger A, Diuguid D, et al. Clinically suspected heparin-induced thrombocytopenia during extracorporeal membrane oxygenation. J Crit Care. 2015;30(6):1190–4.CrossRef
22.
go back to reference Sokolovic M, Pratt AK, Vukicevic V, Sarumi M, Johnson LS, Shah NS. Platelet count trends and prevalence of heparin-induced thrombocytopenia in a cohort of extracorporeal membrane oxygenator patients. Crit Care Med. 2016;44(11):e1031–7.CrossRef Sokolovic M, Pratt AK, Vukicevic V, Sarumi M, Johnson LS, Shah NS. Platelet count trends and prevalence of heparin-induced thrombocytopenia in a cohort of extracorporeal membrane oxygenator patients. Crit Care Med. 2016;44(11):e1031–7.CrossRef
23.
go back to reference Greinacher A, Farner B, Kroll H, Kohlmann T, Warkentin TE, Eichler P. Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. a retrospective analysis of 408 patients. Thromb Haemost. 2005;94(1):132–5. Greinacher A, Farner B, Kroll H, Kohlmann T, Warkentin TE, Eichler P. Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. a retrospective analysis of 408 patients. Thromb Haemost. 2005;94(1):132–5.
24.
go back to reference Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med. 1996;101(5):502–7.CrossRef Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med. 1996;101(5):502–7.CrossRef
25.
go back to reference Gates R, Yost P, Parker B. The use of bivalirudin for cardiopulmonary bypass anticoagulation in pediatric heparin-induced thrombocytopenia patients. Artif Organs. 2010;34(8):667–9. Gates R, Yost P, Parker B. The use of bivalirudin for cardiopulmonary bypass anticoagulation in pediatric heparin-induced thrombocytopenia patients. Artif Organs. 2010;34(8):667–9.
26.
go back to reference Erdoes G, Ortmann E, Martinez Lopez De Arroyabe B, Reid C, Koster A. Role of Bivalirudin for Anticoagulation in Adult Perioperative Cardiothoracic Practice. J Cardiothorac Vasc Anesth. 2020;34(8):2207–14. Erdoes G, Ortmann E, Martinez Lopez De Arroyabe B, Reid C, Koster A. Role of Bivalirudin for Anticoagulation in Adult Perioperative Cardiothoracic Practice. J Cardiothorac Vasc Anesth. 2020;34(8):2207–14.
27.
go back to reference Walker EA, Roberts AJ, Louie EL, Dager WE. Bivalirudin dosing requirements in adult patients on extracorporeal life support with or without continuous renal replacement therapy. Asaio j. 2019;65(2):134–8.CrossRef Walker EA, Roberts AJ, Louie EL, Dager WE. Bivalirudin dosing requirements in adult patients on extracorporeal life support with or without continuous renal replacement therapy. Asaio j. 2019;65(2):134–8.CrossRef
28.
go back to reference Hirsh J, O’Donnell M, Weitz JI. New anticoagulants. Blood. 2005;105(2):453–63.CrossRef Hirsh J, O’Donnell M, Weitz JI. New anticoagulants. Blood. 2005;105(2):453–63.CrossRef
29.
go back to reference Hirsh J, O’Donnell M, Eikelboom JW. Beyond unfractionated heparin and warfarin: current and future advances. Circulation. 2007;116(5):552–60.CrossRef Hirsh J, O’Donnell M, Eikelboom JW. Beyond unfractionated heparin and warfarin: current and future advances. Circulation. 2007;116(5):552–60.CrossRef
30.
go back to reference Berei TJ, Lillyblad MP, Wilson KJ, Garberich RF, Hryniewicz KM. Evaluation of systemic heparin versus bivalirudin in adult patients supported by extracorporeal membrane oxygenation. Asaio j. 2018;64(5):623–9.CrossRef Berei TJ, Lillyblad MP, Wilson KJ, Garberich RF, Hryniewicz KM. Evaluation of systemic heparin versus bivalirudin in adult patients supported by extracorporeal membrane oxygenation. Asaio j. 2018;64(5):623–9.CrossRef
31.
go back to reference Horwitz JR, Cofer BR, Warner BW, Cheu HW, Lally KP. A multicenter trial of 6-aminocaproic acid (Amicar) in the prevention of bleeding in infants on ECMO. J Pediatr Surg. 1998;33(11):1610–3.CrossRef Horwitz JR, Cofer BR, Warner BW, Cheu HW, Lally KP. A multicenter trial of 6-aminocaproic acid (Amicar) in the prevention of bleeding in infants on ECMO. J Pediatr Surg. 1998;33(11):1610–3.CrossRef
32.
go back to reference Pappalardo F, Maj G, Scandroglio A, Sampietro F, Zangrillo A, Koster A. Bioline heparin-coated ECMO with bivalirudin anticoagulation in a patient with acute heparin-induced thrombocytopenia: the immune reaction appeared to continue unabated. Perfusion. 2009;24(2):135–7.CrossRef Pappalardo F, Maj G, Scandroglio A, Sampietro F, Zangrillo A, Koster A. Bioline heparin-coated ECMO with bivalirudin anticoagulation in a patient with acute heparin-induced thrombocytopenia: the immune reaction appeared to continue unabated. Perfusion. 2009;24(2):135–7.CrossRef
33.
go back to reference Koster A, Weng Y, Böttcher W, Gromann T, Kuppe H, Hetzer R. Successful use of bivalirudin as anticoagulant for ECMO in a patient with acute HIT. Ann Thorac Surg. 2007;83(5):1865–7.CrossRef Koster A, Weng Y, Böttcher W, Gromann T, Kuppe H, Hetzer R. Successful use of bivalirudin as anticoagulant for ECMO in a patient with acute HIT. Ann Thorac Surg. 2007;83(5):1865–7.CrossRef
34.
go back to reference Ranucci M, Ballotta A, Kandil H, Isgrò G, Carlucci C, Baryshnikova E, et al. Bivalirudin-based versus conventional heparin anticoagulation for postcardiotomy extracorporeal membrane oxygenation. Crit Care. 2011;15(6):R275.CrossRef Ranucci M, Ballotta A, Kandil H, Isgrò G, Carlucci C, Baryshnikova E, et al. Bivalirudin-based versus conventional heparin anticoagulation for postcardiotomy extracorporeal membrane oxygenation. Crit Care. 2011;15(6):R275.CrossRef
35.
go back to reference Wong JJ-M, Lam JCM, Mok YH, Lee JH. Anticoagulation in extracorporeal membrane oxygenation. J Emergency Crit Care Med. 2018;2:12.CrossRef Wong JJ-M, Lam JCM, Mok YH, Lee JH. Anticoagulation in extracorporeal membrane oxygenation. J Emergency Crit Care Med. 2018;2:12.CrossRef
36.
go back to reference Nagle EL, Dager WE, Duby JJ, Roberts AJ, Kenny LE, Murthy MS, et al. Bivalirudin in pediatric patients maintained on extracorporeal life support. Pediatr Crit Care Med. 2013;14(4):e182–8.CrossRef Nagle EL, Dager WE, Duby JJ, Roberts AJ, Kenny LE, Murthy MS, et al. Bivalirudin in pediatric patients maintained on extracorporeal life support. Pediatr Crit Care Med. 2013;14(4):e182–8.CrossRef
37.
go back to reference Casserly IP, Kereiakes DJ, Gray WA, Gibson PH, Lauer MA, Reginelli JP, et al. Point-of-care ecarin clotting time versus activated clotting time in correlation with bivalirudin concentration. Thromb Res. 2004;113(2):115–21.CrossRef Casserly IP, Kereiakes DJ, Gray WA, Gibson PH, Lauer MA, Reginelli JP, et al. Point-of-care ecarin clotting time versus activated clotting time in correlation with bivalirudin concentration. Thromb Res. 2004;113(2):115–21.CrossRef
38.
go back to reference Pieri M, Agracheva N, Bonaveglio E, Greco T, De Bonis M, Covello RD, et al. Bivalirudin versus heparin as an anticoagulant during extracorporeal membrane oxygenation: a case-control study. J Cardiothorac Vasc Anesth. 2013;27(1):30–4.CrossRef Pieri M, Agracheva N, Bonaveglio E, Greco T, De Bonis M, Covello RD, et al. Bivalirudin versus heparin as an anticoagulant during extracorporeal membrane oxygenation: a case-control study. J Cardiothorac Vasc Anesth. 2013;27(1):30–4.CrossRef
39.
go back to reference Jyoti A, Maheshwari A, Daniel E, Motihar A, Bhathiwal RS, Sharma D. Bivalirudin in venovenous extracorporeal membrane oxygenation. J Extra Corpor Technol. 2014;46(1):94–7. Jyoti A, Maheshwari A, Daniel E, Motihar A, Bhathiwal RS, Sharma D. Bivalirudin in venovenous extracorporeal membrane oxygenation. J Extra Corpor Technol. 2014;46(1):94–7.
40.
go back to reference M’Pembele R, Roth S, Metzger A, Nucaro A, Stroda A, Polzin A, et al. Evaluation of clinical outcomes in patients treated with heparin or direct thrombin inhibitors during extracorporeal membrane oxygenation: a systematic review and meta-analysis. Thromb J. 2022;20(1):42.CrossRef M’Pembele R, Roth S, Metzger A, Nucaro A, Stroda A, Polzin A, et al. Evaluation of clinical outcomes in patients treated with heparin or direct thrombin inhibitors during extracorporeal membrane oxygenation: a systematic review and meta-analysis. Thromb J. 2022;20(1):42.CrossRef
41.
go back to reference Tsu LV, Dager WE. Bivalirudin dosing adjustments for reduced renal function with or without hemodialysis in the management of heparin-induced thrombocytopenia. Ann Pharmacother. 2011;45(10):1185–92.CrossRef Tsu LV, Dager WE. Bivalirudin dosing adjustments for reduced renal function with or without hemodialysis in the management of heparin-induced thrombocytopenia. Ann Pharmacother. 2011;45(10):1185–92.CrossRef
42.
go back to reference Ranucci M. Bivalirudin and post-cardiotomy ECMO: a word of caution. Crit Care. 2012;16(3):427.CrossRef Ranucci M. Bivalirudin and post-cardiotomy ECMO: a word of caution. Crit Care. 2012;16(3):427.CrossRef
43.
go back to reference Cardinale M, Ha M, Liu MH, Reardon DP. Direct Thrombin Inhibitor Resistance and Possible Mechanisms. Hosp Pharm. 2016;51(11):922–7.CrossRef Cardinale M, Ha M, Liu MH, Reardon DP. Direct Thrombin Inhibitor Resistance and Possible Mechanisms. Hosp Pharm. 2016;51(11):922–7.CrossRef
44.
go back to reference Schmid C. Extracorporeal Circulation and Myocardial Protection in Adult Cardiac Surgery. Cardiac Surgery: Springer; 2017. p. 111–52. Schmid C. Extracorporeal Circulation and Myocardial Protection in Adult Cardiac Surgery. Cardiac Surgery: Springer; 2017. p. 111–52.
45.
go back to reference Koster A, Weng Y, Böttcher W, Gromann T, Kuppe H, Hetzer R. Successful use of bivalirudin as anticoagulant for ECMO in a patient with acute HIT. Ann Thorac Surg. 2007;83(5):1865–7.CrossRef Koster A, Weng Y, Böttcher W, Gromann T, Kuppe H, Hetzer R. Successful use of bivalirudin as anticoagulant for ECMO in a patient with acute HIT. Ann Thorac Surg. 2007;83(5):1865–7.CrossRef
46.
go back to reference van der Staak FH, de Haan AF, Geven WB, Festen C. Surgical repair of congenital diaphragmatic hernia during extracorporeal membrane oxygenation: hemorrhagic complications and the effect of tranexamic acid. J Pediatr Surg. 1997;32(4):594–9.CrossRef van der Staak FH, de Haan AF, Geven WB, Festen C. Surgical repair of congenital diaphragmatic hernia during extracorporeal membrane oxygenation: hemorrhagic complications and the effect of tranexamic acid. J Pediatr Surg. 1997;32(4):594–9.CrossRef
47.
go back to reference Young G, Yonekawa KE, Nakagawa P, Nugent DJ. Argatroban as an alternative to heparin in extracorporeal membrane oxygenation circuits. Perfusion. 2004;19(5):283–8.CrossRef Young G, Yonekawa KE, Nakagawa P, Nugent DJ. Argatroban as an alternative to heparin in extracorporeal membrane oxygenation circuits. Perfusion. 2004;19(5):283–8.CrossRef
48.
go back to reference Phillips MR, Khoury AI, Ashton RF, Cairns BA, Charles AG. The dosing and monitoring of argatroban for heparin-induced thrombocytopenia during extracorporeal membrane oxygenation: a word of caution. Anaesth Intensive Care. 2014;42(1):97–8.CrossRef Phillips MR, Khoury AI, Ashton RF, Cairns BA, Charles AG. The dosing and monitoring of argatroban for heparin-induced thrombocytopenia during extracorporeal membrane oxygenation: a word of caution. Anaesth Intensive Care. 2014;42(1):97–8.CrossRef
49.
go back to reference Warkentin TE, Cook RJ, Marder VJ, Sheppard JA, Moore JC, Eriksson BI, et al. Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. Blood. 2005;106(12):3791–6.CrossRef Warkentin TE, Cook RJ, Marder VJ, Sheppard JA, Moore JC, Eriksson BI, et al. Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. Blood. 2005;106(12):3791–6.CrossRef
50.
go back to reference Parlar AI, Sayar U, Cevirme D, Yuruk MA, Mataraci I. Successful use of fondaparinux in a patient with heparin-induced thrombocytopenia while on extracorporeal membrane oxygenation after mitral valve redo surgery. Int J Artif Organs. 2014;37(4):344–7.CrossRef Parlar AI, Sayar U, Cevirme D, Yuruk MA, Mataraci I. Successful use of fondaparinux in a patient with heparin-induced thrombocytopenia while on extracorporeal membrane oxygenation after mitral valve redo surgery. Int J Artif Organs. 2014;37(4):344–7.CrossRef
51.
go back to reference Greinacher A, Warkentin TE. The direct thrombin inhibitor hirudin. Thromb Haemost. 2008;99(5):819–29. Greinacher A, Warkentin TE. The direct thrombin inhibitor hirudin. Thromb Haemost. 2008;99(5):819–29.
52.
go back to reference Ota T, Okada K, Kano H, Okita Y. Cardiopulmonary bypass using nafamostat mesilate for patients with infective endocarditis and recent intracranial hemorrhage. Interact Cardiovasc Thorac Surg. 2007;6(3):270–3.CrossRef Ota T, Okada K, Kano H, Okita Y. Cardiopulmonary bypass using nafamostat mesilate for patients with infective endocarditis and recent intracranial hemorrhage. Interact Cardiovasc Thorac Surg. 2007;6(3):270–3.CrossRef
53.
go back to reference Lim JY, Kim JB, Choo SJ, Chung CH, Lee JW, Jung SH. Anticoagulation during extracorporeal membrane oxygenation; nafamostat mesilate versus heparin. Ann Thorac Surg. 2016;102(2):534–9.CrossRef Lim JY, Kim JB, Choo SJ, Chung CH, Lee JW, Jung SH. Anticoagulation during extracorporeal membrane oxygenation; nafamostat mesilate versus heparin. Ann Thorac Surg. 2016;102(2):534–9.CrossRef
54.
go back to reference Park JH, Her C, Min HK, Kim DK, Park SH, Jang HJ. Nafamostat mesilate as a regional anticoagulant in patients with bleeding complications during extracorporeal membrane oxygenation. Int J Artif Organs. 2015;38(11):595–9.CrossRef Park JH, Her C, Min HK, Kim DK, Park SH, Jang HJ. Nafamostat mesilate as a regional anticoagulant in patients with bleeding complications during extracorporeal membrane oxygenation. Int J Artif Organs. 2015;38(11):595–9.CrossRef
55.
go back to reference Han SJ, Kim HS, Kim KI, Whang SM, Hong KS, Lee WK, et al. Use of nafamostat mesilate as an anticoagulant during extracorporeal membrane oxygenation. J Korean Med Sci. 2011;26(7):945–50.CrossRef Han SJ, Kim HS, Kim KI, Whang SM, Hong KS, Lee WK, et al. Use of nafamostat mesilate as an anticoagulant during extracorporeal membrane oxygenation. J Korean Med Sci. 2011;26(7):945–50.CrossRef
56.
go back to reference Nagaya M, Futamura M, Kato J, Niimi N, Fukuta S. Application of a new anticoagulant (Nafamostat Mesilate) to control hemorrhagic complications during extracorporeal membrane oxygenation–a preliminary report. J Pediatr Surg. 1997;32(4):531–5.CrossRef Nagaya M, Futamura M, Kato J, Niimi N, Fukuta S. Application of a new anticoagulant (Nafamostat Mesilate) to control hemorrhagic complications during extracorporeal membrane oxygenation–a preliminary report. J Pediatr Surg. 1997;32(4):531–5.CrossRef
57.
58.
go back to reference Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 Suppl):311s-37s. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 Suppl):311s-37s.
59.
go back to reference Hirsh J, Fuster V, Ansell J, Halperin JL. american heart association/american college of cardiology foundation guide to warfarin therapy. Circulation. 2003;107(12):1692–711.CrossRef Hirsh J, Fuster V, Ansell J, Halperin JL. american heart association/american college of cardiology foundation guide to warfarin therapy. Circulation. 2003;107(12):1692–711.CrossRef
60.
go back to reference Lee JH, Kim SW. Successful management of warfarin-exacerbated diffuse alveolar hemorrhage using an extracorporeal membrane oxygenation. Multidiscip Respir Med. 2013;8(1):16.CrossRef Lee JH, Kim SW. Successful management of warfarin-exacerbated diffuse alveolar hemorrhage using an extracorporeal membrane oxygenation. Multidiscip Respir Med. 2013;8(1):16.CrossRef
61.
go back to reference Nguyen TP, Phan XT, Huynh DQ, Viet Truong HT, Hai Le YN, Nguyen TM, et al. Monitoring Unfractionated Heparin in Adult Patients Undergoing Extracorporeal Membrane Oxygenation (ECMO): ACT, APTT, or ANTI-XA? Crit Care Res Pract. 2021;2021:5579936. Nguyen TP, Phan XT, Huynh DQ, Viet Truong HT, Hai Le YN, Nguyen TM, et al. Monitoring Unfractionated Heparin in Adult Patients Undergoing Extracorporeal Membrane Oxygenation (ECMO): ACT, APTT, or ANTI-XA? Crit Care Res Pract. 2021;2021:5579936.
62.
go back to reference Teruya J, Bruzdoski K, Hensch L, Hui SKR, Kostousov V. How to best monitor bivalirudin anticoagulant effect for ECMO and VAD—Comparison of four assay methods. Int J Lab Hematol. 2022;44(3):589–94. Teruya J, Bruzdoski K, Hensch L, Hui SKR, Kostousov V. How to best monitor bivalirudin anticoagulant effect for ECMO and VAD—Comparison of four assay methods. Int J Lab Hematol. 2022;44(3):589–94.
63.
go back to reference Fisser C, Winkler M, Malfertheiner MV, Philipp A, Foltan M, Lunz D, et al. Argatroban versus heparin in patients without heparin-induced thrombocytopenia during venovenous extracorporeal membrane oxygenation: a propensity-score matched study. Crit Care. 2021;25(1):1–10.CrossRef Fisser C, Winkler M, Malfertheiner MV, Philipp A, Foltan M, Lunz D, et al. Argatroban versus heparin in patients without heparin-induced thrombocytopenia during venovenous extracorporeal membrane oxygenation: a propensity-score matched study. Crit Care. 2021;25(1):1–10.CrossRef
64.
go back to reference Myllylahti L, Pitkänen H, Magnani H, Lassila R. Experience of danaparoid to treat vaccine-induced immune thrombocytopenia and thrombosis, VITT. Thromb J. 2022;20(1):4.CrossRef Myllylahti L, Pitkänen H, Magnani H, Lassila R. Experience of danaparoid to treat vaccine-induced immune thrombocytopenia and thrombosis, VITT. Thromb J. 2022;20(1):4.CrossRef
65.
go back to reference Serasli E, Antoniadou M, Tsara V, Kalpakidis V, Megalopoulos A, Trellopoulos G, et al. Successful management of acute thromboembolic disease complicated with heparin induced thrombocytopenia type II (HIT II): a case series. Thromb J. 2008;6(1):9.CrossRef Serasli E, Antoniadou M, Tsara V, Kalpakidis V, Megalopoulos A, Trellopoulos G, et al. Successful management of acute thromboembolic disease complicated with heparin induced thrombocytopenia type II (HIT II): a case series. Thromb J. 2008;6(1):9.CrossRef
66.
go back to reference Moon K, Hong K-W, Bae I-G. Treatment effect of nafamostat mesylate in patients with COVID-19 pneumonia: study protocol for a randomized controlled trial. Trials. 2021;22(1):832.CrossRef Moon K, Hong K-W, Bae I-G. Treatment effect of nafamostat mesylate in patients with COVID-19 pneumonia: study protocol for a randomized controlled trial. Trials. 2021;22(1):832.CrossRef
67.
go back to reference Lippi G, Favaloro EJ. Laboratory monitoring of warfarin in the era of direct oral anticoagulants. The Lancet Haematology. 2015;2(6):e223–4.CrossRef Lippi G, Favaloro EJ. Laboratory monitoring of warfarin in the era of direct oral anticoagulants. The Lancet Haematology. 2015;2(6):e223–4.CrossRef
68.
go back to reference Tralhão A, Aguiar C, Ferreira J, Rebocho MJ, Santos E, Martins D, et al. Dabigatran reversal with idarucizumab in a patient undergoing heart transplantation: first European report. Thromb J. 2017;15(1):23.CrossRef Tralhão A, Aguiar C, Ferreira J, Rebocho MJ, Santos E, Martins D, et al. Dabigatran reversal with idarucizumab in a patient undergoing heart transplantation: first European report. Thromb J. 2017;15(1):23.CrossRef
69.
go back to reference Harder S. Pharmacokinetic and pharmacodynamic evaluation of rivaroxaban: considerations for the treatment of venous thromboembolism. Thromb J. 2014;12(1):22.CrossRef Harder S. Pharmacokinetic and pharmacodynamic evaluation of rivaroxaban: considerations for the treatment of venous thromboembolism. Thromb J. 2014;12(1):22.CrossRef
70.
go back to reference Berk ZB, Shah A, Sun W, Griffith BP, Wu ZJ. An ex vivo comparison of partial thromboplastin time and activated clotting time for heparin anticoagulation in an ovine model. Artif Organs. 2022;46(3):501–5.CrossRef Berk ZB, Shah A, Sun W, Griffith BP, Wu ZJ. An ex vivo comparison of partial thromboplastin time and activated clotting time for heparin anticoagulation in an ovine model. Artif Organs. 2022;46(3):501–5.CrossRef
71.
go back to reference Honore PM, Barreto Gutierrez L, Kugener L, Redant S, Attou R, Gallerani A, et al. Use of multiple laboratory tests including anti-factor Xa to optimally manage anticoagulation during ECMO. Crit Care. 2020;24(1):427.CrossRef Honore PM, Barreto Gutierrez L, Kugener L, Redant S, Attou R, Gallerani A, et al. Use of multiple laboratory tests including anti-factor Xa to optimally manage anticoagulation during ECMO. Crit Care. 2020;24(1):427.CrossRef
72.
go back to reference Villalba CAF, Brogan TV, McMullan DM, Yalon L, Jordan DI, Chandler WL. Conversion from activated clotting time to anti-Xa heparin activity assay for heparin monitoring during extracorporeal membrane oxygenation. Crit Care Med. 2020;48(12):e1179–84.CrossRef Villalba CAF, Brogan TV, McMullan DM, Yalon L, Jordan DI, Chandler WL. Conversion from activated clotting time to anti-Xa heparin activity assay for heparin monitoring during extracorporeal membrane oxygenation. Crit Care Med. 2020;48(12):e1179–84.CrossRef
73.
go back to reference Chandel A, Patolia S, Looby M, Bade N, Khangoora V, King CS. Association of D-dimer and fibrinogen with hypercoagulability in COVID-19 requiring extracorporeal membrane oxygenation. J Intensive Care Med. 2021;36(6):689–95.CrossRef Chandel A, Patolia S, Looby M, Bade N, Khangoora V, King CS. Association of D-dimer and fibrinogen with hypercoagulability in COVID-19 requiring extracorporeal membrane oxygenation. J Intensive Care Med. 2021;36(6):689–95.CrossRef
74.
go back to reference Onundarson PT, Francis CW, Indridason OS, Arnar DO, Bjornsson ES, Magnusson MK, et al. Fiix-prothrombin time versus standard prothrombin time for monitoring of warfarin anticoagulation: a single centre, double-blind, randomised, non-inferiority trial. The Lancet Haematology. 2015;2(6):e231–40.CrossRef Onundarson PT, Francis CW, Indridason OS, Arnar DO, Bjornsson ES, Magnusson MK, et al. Fiix-prothrombin time versus standard prothrombin time for monitoring of warfarin anticoagulation: a single centre, double-blind, randomised, non-inferiority trial. The Lancet Haematology. 2015;2(6):e231–40.CrossRef
75.
go back to reference Gosselin RC, Douxfils J. Ecarin based coagulation testing. Am J Hematol. 2020;95(7):863–9.CrossRef Gosselin RC, Douxfils J. Ecarin based coagulation testing. Am J Hematol. 2020;95(7):863–9.CrossRef
76.
go back to reference Olson JD, Arkin CF, Brandt JT, Cunningham MT, Giles A, Koepke JA, et al. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: laboratory monitoring of unfractionated heparin therapy. Arch Pathol Lab Med. 1998;122(9):782–98. Olson JD, Arkin CF, Brandt JT, Cunningham MT, Giles A, Koepke JA, et al. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: laboratory monitoring of unfractionated heparin therapy. Arch Pathol Lab Med. 1998;122(9):782–98.
77.
go back to reference Mohammadi Aria M, Erten A, Yalcin O. Technology advancements in blood coagulation measurements for point-of-care diagnostic testing. Front Bioeng Biotechnol. 2019;7:395.CrossRef Mohammadi Aria M, Erten A, Yalcin O. Technology advancements in blood coagulation measurements for point-of-care diagnostic testing. Front Bioeng Biotechnol. 2019;7:395.CrossRef
78.
go back to reference Ignjatovic V. Activated partial thromboplastin time. Methods Mol Biol. 2013;992:111–20.CrossRef Ignjatovic V. Activated partial thromboplastin time. Methods Mol Biol. 2013;992:111–20.CrossRef
79.
go back to reference Baglin T, Barrowcliffe TW, Cohen A, Greaves M. Guidelines on the use and monitoring of heparin. Br J Haematol. 2006;133(1):19–34.CrossRef Baglin T, Barrowcliffe TW, Cohen A, Greaves M. Guidelines on the use and monitoring of heparin. Br J Haematol. 2006;133(1):19–34.CrossRef
80.
go back to reference Ogawa F, Oi Y, Nakajima K, Matsumura R, Nakagawa T, Miyagawa T, et al. An evaluation of venous thromboembolism by whole-body enhanced CT scan for critical COVID-19 pneumonia with markedly rises of coagulopathy related factors: a case series study. Thromb J. 2021;19(1):26.CrossRef Ogawa F, Oi Y, Nakajima K, Matsumura R, Nakagawa T, Miyagawa T, et al. An evaluation of venous thromboembolism by whole-body enhanced CT scan for critical COVID-19 pneumonia with markedly rises of coagulopathy related factors: a case series study. Thromb J. 2021;19(1):26.CrossRef
81.
go back to reference Bates SM, Weitz JI, Johnston M, Hirsh J, Ginsberg JS. Use of a fixed activated partial thromboplastin time ratio to establish a therapeutic range for unfractionated heparin. Arch Intern Med. 2001;161(3):385–91.CrossRef Bates SM, Weitz JI, Johnston M, Hirsh J, Ginsberg JS. Use of a fixed activated partial thromboplastin time ratio to establish a therapeutic range for unfractionated heparin. Arch Intern Med. 2001;161(3):385–91.CrossRef
82.
go back to reference Price EA, Jin J, Nguyen HM, Krishnan G, Bowen R, Zehnder JL. Discordant aPTT and anti-Xa values and outcomes in hospitalized patients treated with intravenous unfractionated heparin. Ann Pharmacother. 2013;47(2):151–8.CrossRef Price EA, Jin J, Nguyen HM, Krishnan G, Bowen R, Zehnder JL. Discordant aPTT and anti-Xa values and outcomes in hospitalized patients treated with intravenous unfractionated heparin. Ann Pharmacother. 2013;47(2):151–8.CrossRef
83.
go back to reference Kitchen S. Problems in laboratory monitoring of heparin dosage. Br J Haematol. 2000;111(2):397–406. Kitchen S. Problems in laboratory monitoring of heparin dosage. Br J Haematol. 2000;111(2):397–406.
84.
go back to reference Newall F. Anti-factor Xa (anti-Xa) assay. Methods Mol Biol. 2013;992:265–72.CrossRef Newall F. Anti-factor Xa (anti-Xa) assay. Methods Mol Biol. 2013;992:265–72.CrossRef
85.
go back to reference Gehrie E, Laposata M. Test of the month: the chromogenic antifactor Xa assay. Am J Hematol. 2012;87(2):194–6.CrossRef Gehrie E, Laposata M. Test of the month: the chromogenic antifactor Xa assay. Am J Hematol. 2012;87(2):194–6.CrossRef
86.
go back to reference Khaja WA, Bilen O, Lukner RB, Edwards R, Teruya J. Evaluation of heparin assay for coagulation management in newborns undergoing ECMO. Am J Clin Pathol. 2010;134(6):950–4.CrossRef Khaja WA, Bilen O, Lukner RB, Edwards R, Teruya J. Evaluation of heparin assay for coagulation management in newborns undergoing ECMO. Am J Clin Pathol. 2010;134(6):950–4.CrossRef
87.
go back to reference Ignjatovic V, Lai C, Summerhayes R, Mathesius U, Tawfilis S, Perugini MA, et al. Age-related differences in plasma proteins: how plasma proteins change from neonates to adults. PLoS ONE. 2011;6(2): e17213.CrossRef Ignjatovic V, Lai C, Summerhayes R, Mathesius U, Tawfilis S, Perugini MA, et al. Age-related differences in plasma proteins: how plasma proteins change from neonates to adults. PLoS ONE. 2011;6(2): e17213.CrossRef
88.
go back to reference Vera-Aguilera J, Yousef H, Beltran-Melgarejo D, Teng TH, Jan R, Mok M, et al. Clinical scenarios for discordant anti-xa. Adv Hematol. 2016;2016:4054806.CrossRef Vera-Aguilera J, Yousef H, Beltran-Melgarejo D, Teng TH, Jan R, Mok M, et al. Clinical scenarios for discordant anti-xa. Adv Hematol. 2016;2016:4054806.CrossRef
89.
go back to reference Ranucci M, Cotza M, Isgrò G, Carboni G, Ballotta A, Baryshnikova E. Anti-factor xa-based anticoagulation during extracorporeal membrane oxygenation: potential problems and possible solutions. Semin Thromb Hemost. 2020;46(4):419–27.CrossRef Ranucci M, Cotza M, Isgrò G, Carboni G, Ballotta A, Baryshnikova E. Anti-factor xa-based anticoagulation during extracorporeal membrane oxygenation: potential problems and possible solutions. Semin Thromb Hemost. 2020;46(4):419–27.CrossRef
90.
go back to reference Kostousov V, Nguyen K, Hundalani SG, Teruya J. The influence of free hemoglobin and bilirubin on heparin monitoring by activated partial thromboplastin time and anti-Xa assay. Arch Pathol Lab Med. 2014;138(11):1503–6.CrossRef Kostousov V, Nguyen K, Hundalani SG, Teruya J. The influence of free hemoglobin and bilirubin on heparin monitoring by activated partial thromboplastin time and anti-Xa assay. Arch Pathol Lab Med. 2014;138(11):1503–6.CrossRef
91.
go back to reference Liveris A, Bello RA, Friedmann P, Duffy MA, Manwani D, Killinger JS, et al. Anti-factor Xa assay is a superior correlate of heparin dose than activated partial thromboplastin time or activated clotting time in pediatric extracorporeal membrane oxygenation*. Pediatr Crit Care Med. 2014;15(2):e72–9.CrossRef Liveris A, Bello RA, Friedmann P, Duffy MA, Manwani D, Killinger JS, et al. Anti-factor Xa assay is a superior correlate of heparin dose than activated partial thromboplastin time or activated clotting time in pediatric extracorporeal membrane oxygenation*. Pediatr Crit Care Med. 2014;15(2):e72–9.CrossRef
92.
go back to reference Delmas C, Jacquemin A, Vardon-Bounes F, Georges B, Guerrero F, Hernandez N, et al. Anticoagulation monitoring under ECMO support: a comparative study between the activated coagulation time and the anti-xa activity assay. J Intensive Care Med. 2020;35(7):679–86.CrossRef Delmas C, Jacquemin A, Vardon-Bounes F, Georges B, Guerrero F, Hernandez N, et al. Anticoagulation monitoring under ECMO support: a comparative study between the activated coagulation time and the anti-xa activity assay. J Intensive Care Med. 2020;35(7):679–86.CrossRef
93.
go back to reference O’Meara LC, Alten JA, Goldberg KG, Timpa JG, Phillips J, Laney D, et al. Anti-xa directed protocol for anticoagulation management in children supported with extracorporeal membrane oxygenation. Asaio j. 2015;61(3):339–44.CrossRef O’Meara LC, Alten JA, Goldberg KG, Timpa JG, Phillips J, Laney D, et al. Anti-xa directed protocol for anticoagulation management in children supported with extracorporeal membrane oxygenation. Asaio j. 2015;61(3):339–44.CrossRef
94.
go back to reference Nankervis CA, Preston TJ, Dysart KC, Wilkinson WD, Chicoine LG, Welty SE, et al. Assessing heparin dosing in neonates on venoarterial extracorporeal membrane oxygenation. Asaio j. 2007;53(1):111–4.CrossRef Nankervis CA, Preston TJ, Dysart KC, Wilkinson WD, Chicoine LG, Welty SE, et al. Assessing heparin dosing in neonates on venoarterial extracorporeal membrane oxygenation. Asaio j. 2007;53(1):111–4.CrossRef
95.
go back to reference Bembea MM, Schwartz JM, Shah N, Colantuoni E, Lehmann CU, Kickler T, et al. Anticoagulation monitoring during pediatric extracorporeal membrane oxygenation. ASAIO Journal (American Society for Artificial Internal Organs: 1992). 2013;59(1):63. Bembea MM, Schwartz JM, Shah N, Colantuoni E, Lehmann CU, Kickler T, et al. Anticoagulation monitoring during pediatric extracorporeal membrane oxygenation. ASAIO Journal (American Society for Artificial Internal Organs: 1992). 2013;59(1):63.
96.
go back to reference Niebler RA, Parker H, Hoffman GM. Impact of anticoagulation and circuit technology on complications during extracorporeal membrane oxygenation. Asaio j. 2019;65(3):270–6.CrossRef Niebler RA, Parker H, Hoffman GM. Impact of anticoagulation and circuit technology on complications during extracorporeal membrane oxygenation. Asaio j. 2019;65(3):270–6.CrossRef
97.
go back to reference Colman E, Yin EB, Laine G, Chatterjee S, Saatee S, Herlihy JP, et al. Evaluation of a heparin monitoring protocol for extracorporeal membrane oxygenation and review of the literature. J Thorac Dis. 2019;11(8):3325–35.CrossRef Colman E, Yin EB, Laine G, Chatterjee S, Saatee S, Herlihy JP, et al. Evaluation of a heparin monitoring protocol for extracorporeal membrane oxygenation and review of the literature. J Thorac Dis. 2019;11(8):3325–35.CrossRef
98.
go back to reference Vandiver JW, Vondracek TG. Antifactor Xa levels versus activated partial thromboplastin time for monitoring unfractionated heparin. Pharmacotherapy. 2012;32(6):546–58.CrossRef Vandiver JW, Vondracek TG. Antifactor Xa levels versus activated partial thromboplastin time for monitoring unfractionated heparin. Pharmacotherapy. 2012;32(6):546–58.CrossRef
99.
go back to reference Horton S, Augustin S. Activated clotting time (ACT). Methods Mol Biol. 2013;992:155–67.CrossRef Horton S, Augustin S. Activated clotting time (ACT). Methods Mol Biol. 2013;992:155–67.CrossRef
100.
go back to reference Finley A, Greenberg C. Heparin sensitivity and resistance: management during cardiopulmonary bypass. Anesth Analg. 2013;116(6):1210–22.CrossRef Finley A, Greenberg C. Heparin sensitivity and resistance: management during cardiopulmonary bypass. Anesth Analg. 2013;116(6):1210–22.CrossRef
101.
go back to reference Baird CW, Zurakowski D, Robinson B, Gandhi S, Burdis-Koch L, Tamblyn J, et al. Anticoagulation and pediatric extracorporeal membrane oxygenation: impact of activated clotting time and heparin dose on survival. Ann Thorac Surg. 2007;83(3):912–9 discussion 9-20.CrossRef Baird CW, Zurakowski D, Robinson B, Gandhi S, Burdis-Koch L, Tamblyn J, et al. Anticoagulation and pediatric extracorporeal membrane oxygenation: impact of activated clotting time and heparin dose on survival. Ann Thorac Surg. 2007;83(3):912–9 discussion 9-20.CrossRef
102.
go back to reference Maul TM, Nelson JS, Wearden PD. Paracorporeal lung devices: thinking outside the box. Front Pediatr. 2018;6:243.CrossRef Maul TM, Nelson JS, Wearden PD. Paracorporeal lung devices: thinking outside the box. Front Pediatr. 2018;6:243.CrossRef
103.
go back to reference Maul TM, Wolff EL, Kuch BA, Rosendorff A, Morell VO, Wearden PD. Activated partial thromboplastin time is a better trending tool in pediatric extracorporeal membrane oxygenation. Pediatr Crit Care Med. 2012;13(6):e363–71.CrossRef Maul TM, Wolff EL, Kuch BA, Rosendorff A, Morell VO, Wearden PD. Activated partial thromboplastin time is a better trending tool in pediatric extracorporeal membrane oxygenation. Pediatr Crit Care Med. 2012;13(6):e363–71.CrossRef
104.
go back to reference Atallah S, Liebl M, Fitousis K, Bostan F, Masud F. Evaluation of the activated clotting time and activated partial thromboplastin time for the monitoring of heparin in adult extracorporeal membrane oxygenation patients. Perfusion. 2014;29(5):456–61.CrossRef Atallah S, Liebl M, Fitousis K, Bostan F, Masud F. Evaluation of the activated clotting time and activated partial thromboplastin time for the monitoring of heparin in adult extracorporeal membrane oxygenation patients. Perfusion. 2014;29(5):456–61.CrossRef
105.
go back to reference Khaja WA, Bilen O, Lukner RB, Edwards R, Teruya J. Evaluation of heparin assay for coagulation management in newborns undergoing ECMO. Am J Clin Pathol. 2010;134(6):950–4.CrossRef Khaja WA, Bilen O, Lukner RB, Edwards R, Teruya J. Evaluation of heparin assay for coagulation management in newborns undergoing ECMO. Am J Clin Pathol. 2010;134(6):950–4.CrossRef
106.
go back to reference Despotis G, Summerfield A, Joist J, Goodnough L, Santoro S, Spitznagel E, et al. Comparison of activated coagulation time and whole blood heparin measurements with laboratory plasma anti-Xa heparin concentration in patients having cardiac operations. J Thorac Cardiovasc Surg. 1994;108(6):1076–82.CrossRef Despotis G, Summerfield A, Joist J, Goodnough L, Santoro S, Spitznagel E, et al. Comparison of activated coagulation time and whole blood heparin measurements with laboratory plasma anti-Xa heparin concentration in patients having cardiac operations. J Thorac Cardiovasc Surg. 1994;108(6):1076–82.CrossRef
107.
go back to reference Colby CE, Sheehan A, Benitz W, Van Meurs K, Halamek LP, Moss RL. Maintaining adequate anticoagulation on extracorporeal membrane oxygenation therapy: Hemochron Junior Low Range versus Hemochron 400. J Extracorporeal Technol. 2003;35(1):35–8. Colby CE, Sheehan A, Benitz W, Van Meurs K, Halamek LP, Moss RL. Maintaining adequate anticoagulation on extracorporeal membrane oxygenation therapy: Hemochron Junior Low Range versus Hemochron 400. J Extracorporeal Technol. 2003;35(1):35–8.
108.
go back to reference Dornia C, Philipp A, Bauer S, Stroszczynski C, Schreyer AG, Müller T, et al. D-dimers are a predictor of clot volume inside membrane oxygenators during extracorporeal membrane oxygenation. Artif Organs. 2015;39(9):782–7.CrossRef Dornia C, Philipp A, Bauer S, Stroszczynski C, Schreyer AG, Müller T, et al. D-dimers are a predictor of clot volume inside membrane oxygenators during extracorporeal membrane oxygenation. Artif Organs. 2015;39(9):782–7.CrossRef
109.
go back to reference Lubnow M, Philipp A, Dornia C, Schroll S, Bein T, Creutzenberg M, et al. D-dimers as an early marker for oxygenator exchange in extracorporeal membrane oxygenation. J Crit Care. 2014;29(3):473.e1-5. Lubnow M, Philipp A, Dornia C, Schroll S, Bein T, Creutzenberg M, et al. D-dimers as an early marker for oxygenator exchange in extracorporeal membrane oxygenation.  J Crit Care. 2014;29(3):473.e1-5.
110.
go back to reference Ignjatovic V. Prothrombin time/international normalized ratio. Methods Mol Biol. 2013;992:121–9.CrossRef Ignjatovic V. Prothrombin time/international normalized ratio. Methods Mol Biol. 2013;992:121–9.CrossRef
111.
go back to reference Shahangian S, LaBeau KM, Howerton DA. Prothrombin time testing practices: adherence to guidelines and standards. Clin Chem. 2006;52(5):793–4.CrossRef Shahangian S, LaBeau KM, Howerton DA. Prothrombin time testing practices: adherence to guidelines and standards. Clin Chem. 2006;52(5):793–4.CrossRef
112.
go back to reference Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: american college of chest physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):e44S-e88S.CrossRef Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: american college of chest physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):e44S-e88S.CrossRef
113.
go back to reference Warkentin TE, Greinacher A, Craven S, Dewar L, Sheppard JA, Ofosu FA. Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation. Thromb Haemost. 2005;94(5):958–64. Warkentin TE, Greinacher A, Craven S, Dewar L, Sheppard JA, Ofosu FA. Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation. Thromb Haemost. 2005;94(5):958–64.
114.
go back to reference Steinlechner B, Kargl G, Schlömmer C, Holaubek C, Scheriau G, Eichinger S, et al. Can heparin-coated ECMO cannulas induce thrombocytopenia in COVID-19 patients? Case Reports Immunol. 2021;2021:6624682.CrossRef Steinlechner B, Kargl G, Schlömmer C, Holaubek C, Scheriau G, Eichinger S, et al. Can heparin-coated ECMO cannulas induce thrombocytopenia in COVID-19 patients? Case Reports Immunol. 2021;2021:6624682.CrossRef
115.
go back to reference Tardy-Poncet B, Nguyen P, Thiranos J-C, Morange P-E, Biron-Andréani C, Gruel Y, et al. Argatroban in the management of heparin-induced thrombocytopenia: a multicenter clinical trial. Crit Care. 2015;19(1):396.CrossRef Tardy-Poncet B, Nguyen P, Thiranos J-C, Morange P-E, Biron-Andréani C, Gruel Y, et al. Argatroban in the management of heparin-induced thrombocytopenia: a multicenter clinical trial. Crit Care. 2015;19(1):396.CrossRef
116.
go back to reference Alouidor B, Sweeney RE, Tat T, Wong RK, Yoon JY. Microfluidic point-of-care ecarin-based clotting and chromogenic assays for monitoring direct thrombin inhibitors. J Extra Corpor Technol. 2019;51(1):29–37. Alouidor B, Sweeney RE, Tat T, Wong RK, Yoon JY. Microfluidic point-of-care ecarin-based clotting and chromogenic assays for monitoring direct thrombin inhibitors. J Extra Corpor Technol. 2019;51(1):29–37.
117.
go back to reference Hans GA, Besser MW. The place of viscoelastic testing in clinical practice. Br J Haematol. 2016;173(1):37–48.CrossRef Hans GA, Besser MW. The place of viscoelastic testing in clinical practice. Br J Haematol. 2016;173(1):37–48.CrossRef
118.
go back to reference Nair P, Hoechter DJ, Buscher H, Venkatesh K, Whittam S, Joseph J, et al. Prospective observational study of hemostatic alterations during adult extracorporeal membrane oxygenation (ECMO) using point-of-care thromboelastometry and platelet aggregometry. J Cardiothorac Vasc Anesth. 2015;29(2):288–96.CrossRef Nair P, Hoechter DJ, Buscher H, Venkatesh K, Whittam S, Joseph J, et al. Prospective observational study of hemostatic alterations during adult extracorporeal membrane oxygenation (ECMO) using point-of-care thromboelastometry and platelet aggregometry. J Cardiothorac Vasc Anesth. 2015;29(2):288–96.CrossRef
119.
go back to reference Heubner L, Greiner M, Vicent O, Beyer-Westendorf J, Tiebel O, Scholz U, et al. Predictive ability of viscoelastic testing using ClotPro® for short-term outcome in patients with severe Covid-19 ARDS with or without ECMO therapy: a retrospective study. Thromb J. 2022;20(1):48.CrossRef Heubner L, Greiner M, Vicent O, Beyer-Westendorf J, Tiebel O, Scholz U, et al. Predictive ability of viscoelastic testing using ClotPro® for short-term outcome in patients with severe Covid-19 ARDS with or without ECMO therapy: a retrospective study. Thromb J. 2022;20(1):48.CrossRef
120.
go back to reference Whiting P, Al M, Westwood M, Ramos IC, Ryder S, Armstrong N, et al. Viscoelastic point-of-care testing to assist with the diagnosis, management and monitoring of haemostasis: a systematic review and cost-effectiveness analysis. Health Technol Assess. 2015;19(58):1–228, v−vi.CrossRef Whiting P, Al M, Westwood M, Ramos IC, Ryder S, Armstrong N, et al. Viscoelastic point-of-care testing to assist with the diagnosis, management and monitoring of haemostasis: a systematic review and cost-effectiveness analysis. Health Technol Assess. 2015;19(58):1–228, v−vi.CrossRef
121.
go back to reference Wagner ML, Johnston M, Jenkins T, Palumbo JS, Rymeski BA. Use of thromboelastography in children on extracorporeal membrane oxygenation. J Pediatr Surg. 2022;57(6):1056–61.CrossRef Wagner ML, Johnston M, Jenkins T, Palumbo JS, Rymeski BA. Use of thromboelastography in children on extracorporeal membrane oxygenation. J Pediatr Surg. 2022;57(6):1056–61.CrossRef
122.
go back to reference Herrmann J, Notz Q, Schlesinger T, Stumpner J, Kredel M, Sitter M, et al. Point of care diagnostic of hypercoagulability and platelet function in COVID-19 induced acute respiratory distress syndrome: a retrospective observational study. Thromb J. 2021;19(1):39.CrossRef Herrmann J, Notz Q, Schlesinger T, Stumpner J, Kredel M, Sitter M, et al. Point of care diagnostic of hypercoagulability and platelet function in COVID-19 induced acute respiratory distress syndrome: a retrospective observational study. Thromb J. 2021;19(1):39.CrossRef
123.
go back to reference Zaky A. Thromboelastometry versus rotational thromboelastography in cardiac surgery. Semin Cardiothorac Vasc Anesth. 2017;21(3):206–11.CrossRef Zaky A. Thromboelastometry versus rotational thromboelastography in cardiac surgery. Semin Cardiothorac Vasc Anesth. 2017;21(3):206–11.CrossRef
124.
go back to reference Neethling C, Calligaro G, Miller M, Opie JJS. The evolution of clot strength in critically-ill COVID-19 patients: a prospective observational thromboelastography study. Thromb J. 2021;19(1):83.CrossRef Neethling C, Calligaro G, Miller M, Opie JJS. The evolution of clot strength in critically-ill COVID-19 patients: a prospective observational thromboelastography study. Thromb J. 2021;19(1):83.CrossRef
125.
go back to reference Schmidt DE, Majeed A, Bruzelius M, Odeberg J, Holmström M, Ågren A. A prospective diagnostic accuracy study evaluating rotational thromboelastometry and thromboelastography in 100 patients with von Willebrand disease. Haemophilia. 2017;23(2):309–18.CrossRef Schmidt DE, Majeed A, Bruzelius M, Odeberg J, Holmström M, Ågren A. A prospective diagnostic accuracy study evaluating rotational thromboelastometry and thromboelastography in 100 patients with von Willebrand disease. Haemophilia. 2017;23(2):309–18.CrossRef
126.
go back to reference Bembea MM, Annich G, Rycus P, Oldenburg G, Berkowitz I, Pronovost P. Variability in anticoagulation management of patients on extracorporeal membrane oxygenation: an international survey. Pediatr Crit Care Med. 2013;14(2):e77-84.CrossRef Bembea MM, Annich G, Rycus P, Oldenburg G, Berkowitz I, Pronovost P. Variability in anticoagulation management of patients on extracorporeal membrane oxygenation: an international survey. Pediatr Crit Care Med. 2013;14(2):e77-84.CrossRef
127.
go back to reference Fuchs G, Berg N, Eriksson A, Prahl WL. Detection of thrombosis in the extracorporeal membrane oxygenation circuit by infrasound: proof of concept. Artif Organs. 2017;41(6):573–9.CrossRef Fuchs G, Berg N, Eriksson A, Prahl WL. Detection of thrombosis in the extracorporeal membrane oxygenation circuit by infrasound: proof of concept. Artif Organs. 2017;41(6):573–9.CrossRef
128.
go back to reference Hubbert L, Sundbom P, Loebe M, Peterzén B, Granfeldt H, Ahn H. Acoustic analysis of a mechanical circulatory support. Artif Organs. 2014;38(7):593–8.CrossRef Hubbert L, Sundbom P, Loebe M, Peterzén B, Granfeldt H, Ahn H. Acoustic analysis of a mechanical circulatory support. Artif Organs. 2014;38(7):593–8.CrossRef
129.
go back to reference Morita N, Sakota D, Oota-Ishigaki A, Kosaka R, Maruyama O, Nishida M, et al. Real-time, non-invasive thrombus detection in an extracorporeal circuit using micro-optical thrombus sensors. Int J Artif Organs. 2021;44(8):565–73.CrossRef Morita N, Sakota D, Oota-Ishigaki A, Kosaka R, Maruyama O, Nishida M, et al. Real-time, non-invasive thrombus detection in an extracorporeal circuit using micro-optical thrombus sensors. Int J Artif Organs. 2021;44(8):565–73.CrossRef
130.
go back to reference Fujiwara T, Sakota D, Ohuchi K, Endo S, Tahara T, Murashige T, et al. Optical dynamic analysis of thrombus inside a centrifugal blood pump during extracorporeal mechanical circulatory support in a porcine model. Artif Organs. 2017;41(10):893–903.CrossRef Fujiwara T, Sakota D, Ohuchi K, Endo S, Tahara T, Murashige T, et al. Optical dynamic analysis of thrombus inside a centrifugal blood pump during extracorporeal mechanical circulatory support in a porcine model. Artif Organs. 2017;41(10):893–903.CrossRef
131.
go back to reference Meyer AD, Rishmawi AR, Kamucheka R, Lafleur C, Batchinsky AI, Mackman N, et al. Effect of blood flow on platelets, leukocytes, and extracellular vesicles in thrombosis of simulated neonatal extracorporeal circulation. J Thromb Haemost. 2020;18(2):399–410.CrossRef Meyer AD, Rishmawi AR, Kamucheka R, Lafleur C, Batchinsky AI, Mackman N, et al. Effect of blood flow on platelets, leukocytes, and extracellular vesicles in thrombosis of simulated neonatal extracorporeal circulation. J Thromb Haemost. 2020;18(2):399–410.CrossRef
132.
go back to reference Sun W, Wang S, Chen Z, Zhang J, Li T, Arias K, et al. Impact of high mechanical shear stress and oxygenator membrane surface on blood damage relevant to thrombosis and bleeding in a pediatric ECMO circuit. Artif Organs. 2020;44(7):717–26.CrossRef Sun W, Wang S, Chen Z, Zhang J, Li T, Arias K, et al. Impact of high mechanical shear stress and oxygenator membrane surface on blood damage relevant to thrombosis and bleeding in a pediatric ECMO circuit. Artif Organs. 2020;44(7):717–26.CrossRef
133.
go back to reference Huu DN, Kikuchi D, Maruyama O, Sapkota A, Takei M. Cole-cole analysis of thrombus formation in an extracorporeal blood flow circulation using electrical measurement. Flow Meas Instrum. 2017;53:172–9.CrossRef Huu DN, Kikuchi D, Maruyama O, Sapkota A, Takei M. Cole-cole analysis of thrombus formation in an extracorporeal blood flow circulation using electrical measurement. Flow Meas Instrum. 2017;53:172–9.CrossRef
134.
go back to reference Li J, Sapkota A, Kikuchi D, Sakota D, Maruyama O, Takei M. Red blood cells aggregability measurement of coagulating blood in extracorporeal circulation system with multiple-frequency electrical impedance spectroscopy. Biosens Bioelectron. 2018;112:79–85.CrossRef Li J, Sapkota A, Kikuchi D, Sakota D, Maruyama O, Takei M. Red blood cells aggregability measurement of coagulating blood in extracorporeal circulation system with multiple-frequency electrical impedance spectroscopy. Biosens Bioelectron. 2018;112:79–85.CrossRef
135.
go back to reference Yau JW, Stafford AR, Liao P, Fredenburgh JC, Roberts R, Brash JL, et al. Corn trypsin inhibitor coating attenuates the prothrombotic properties of catheters in vitro and in vivo. Acta Biomater. 2012;8(11):4092–100.CrossRef Yau JW, Stafford AR, Liao P, Fredenburgh JC, Roberts R, Brash JL, et al. Corn trypsin inhibitor coating attenuates the prothrombotic properties of catheters in vitro and in vivo. Acta Biomater. 2012;8(11):4092–100.CrossRef
136.
go back to reference Larsson M, Rayzman V, Nolte MW, Nickel KF, Björkqvist J, Jämsä A, et al. A factor XIIa inhibitory antibody provides thromboprotection in extracorporeal circulation without increasing bleeding risk. Sci Transl Med. 2014;6(222):222ra17.CrossRef Larsson M, Rayzman V, Nolte MW, Nickel KF, Björkqvist J, Jämsä A, et al. A factor XIIa inhibitory antibody provides thromboprotection in extracorporeal circulation without increasing bleeding risk. Sci Transl Med. 2014;6(222):222ra17.CrossRef
137.
go back to reference Weitz JI, Fredenburgh JC. Factors XI and XII as targets for new anticoagulants. Front Med (Lausanne). 2017;4:19. Weitz JI, Fredenburgh JC. Factors XI and XII as targets for new anticoagulants. Front Med (Lausanne). 2017;4:19.
138.
go back to reference Wood KL, Ayers B, Gosev I, Kumar N, Melvin AL, Barrus B, et al. Venoarterial-extracorporeal membrane oxygenation without routine systemic anticoagulation decreases adverse events. Ann Thorac Surg. 2020;109(5):1458–66.CrossRef Wood KL, Ayers B, Gosev I, Kumar N, Melvin AL, Barrus B, et al. Venoarterial-extracorporeal membrane oxygenation without routine systemic anticoagulation decreases adverse events. Ann Thorac Surg. 2020;109(5):1458–66.CrossRef
139.
go back to reference Raman J, Alimohamed M, Dobrilovic N, Lateef O, Aziz S. A comparison of low and standard anti-coagulation regimens in extracorporeal membrane oxygenation. J Heart Lung Transplant. 2019;38(4):433–9.CrossRef Raman J, Alimohamed M, Dobrilovic N, Lateef O, Aziz S. A comparison of low and standard anti-coagulation regimens in extracorporeal membrane oxygenation. J Heart Lung Transplant. 2019;38(4):433–9.CrossRef
140.
go back to reference Carter KT, Kutcher ME, Shake JG, Panos AL, Cochran RP, Creswell LL, et al. Heparin-sparing anticoagulation strategies are viable options for patients on veno-venous ECMO. J Surg Res. 2019;243:399–409.CrossRef Carter KT, Kutcher ME, Shake JG, Panos AL, Cochran RP, Creswell LL, et al. Heparin-sparing anticoagulation strategies are viable options for patients on veno-venous ECMO. J Surg Res. 2019;243:399–409.CrossRef
141.
go back to reference Molloy CP, Yao Y, Kammoun H, Bonnard T, Hoefer T, Alt K, et al. Shear-sensitive nanocapsule drug release for site-specific inhibition of occlusive thrombus formation. J Thromb Haemost. 2017;15(5):972–82.CrossRef Molloy CP, Yao Y, Kammoun H, Bonnard T, Hoefer T, Alt K, et al. Shear-sensitive nanocapsule drug release for site-specific inhibition of occlusive thrombus formation. J Thromb Haemost. 2017;15(5):972–82.CrossRef
142.
go back to reference Hoefer T, Rana A, Niego B, Jagdale S, Albers HJ, Gardiner EE, et al. Targeting shear gradient activated von Willebrand factor by the novel single-chain antibody A1 reduces occlusive thrombus formation in vitro. Haematologica. 2021;106(11):2874–84.CrossRef Hoefer T, Rana A, Niego B, Jagdale S, Albers HJ, Gardiner EE, et al. Targeting shear gradient activated von Willebrand factor by the novel single-chain antibody A1 reduces occlusive thrombus formation in vitro. Haematologica. 2021;106(11):2874–84.CrossRef
143.
go back to reference Zhang M, Pauls JP, Bartnikowski N, Haymet AB, Chan CH, Suen JY, et al. Anti-thrombogenic surface coatings for extracorporeal membrane oxygenation: a narrative review. ACS Biomater Sci Eng. 2021;7(9):4402–19.CrossRef Zhang M, Pauls JP, Bartnikowski N, Haymet AB, Chan CH, Suen JY, et al. Anti-thrombogenic surface coatings for extracorporeal membrane oxygenation: a narrative review. ACS Biomater Sci Eng. 2021;7(9):4402–19.CrossRef
144.
go back to reference Ebner M, Birschmann I, Peter A, Spencer C, Härtig F, Kuhn J, et al. Point-of-care testing for emergency assessment of coagulation in patients treated with direct oral anticoagulants. Crit Care. 2017;21(1):32.CrossRef Ebner M, Birschmann I, Peter A, Spencer C, Härtig F, Kuhn J, et al. Point-of-care testing for emergency assessment of coagulation in patients treated with direct oral anticoagulants. Crit Care. 2017;21(1):32.CrossRef
145.
go back to reference Galien S, Hultström M, Lipcsey M, Stattin K, Frithiof R, Rosén J, et al. Point of care ultrasound screening for deep vein thrombosis in critically ill COVID-19 patients, an observational study. Thromb J. 2021;19(1):38.CrossRef Galien S, Hultström M, Lipcsey M, Stattin K, Frithiof R, Rosén J, et al. Point of care ultrasound screening for deep vein thrombosis in critically ill COVID-19 patients, an observational study. Thromb J. 2021;19(1):38.CrossRef
146.
go back to reference Wool GD. Benefits and pitfalls of point-of-care coagulation testing for anticoagulation management: an ACLPS critical review. Am J Clin Pathol. 2019;151(1):1–17.CrossRef Wool GD. Benefits and pitfalls of point-of-care coagulation testing for anticoagulation management: an ACLPS critical review. Am J Clin Pathol. 2019;151(1):1–17.CrossRef
147.
go back to reference Li D, Liu X, Chai Y, Shan J, Xie Y, Liang Y, et al. Point-of-care blood coagulation assay enabled by printed circuit board-based digital microfluidics. Lab on a Chip. 2022;22(4):709–16. Li D, Liu X, Chai Y, Shan J, Xie Y, Liang Y, et al. Point-of-care blood coagulation assay enabled by printed circuit board-based digital microfluidics. Lab on a Chip. 2022;22(4):709–16.
Metadata
Title
Current and future strategies to monitor and manage coagulation in ECMO patients
Authors
Saeedreza Zeibi Shirejini
Josie Carberry
Zoe K. McQuilten
Aidan J. C. Burrell
Shaun D. Gregory
Christoph E. Hagemeyer
Publication date
01-12-2023
Publisher
BioMed Central
Published in
Thrombosis Journal / Issue 1/2023
Electronic ISSN: 1477-9560
DOI
https://doi.org/10.1186/s12959-023-00452-z

Other articles of this Issue 1/2023

Thrombosis Journal 1/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine